Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy

Abstract

BackgroundPotential relationship between serum soluble programmed cell death ligand 1 and prognosis of small cell lung cancer is not well explored. The aim of the study was to reveal the prognostic significance of serum soluble programmed cell death ligand 1 in patients with small cell lung cancer.MethodsA total of 250 small cell lung cancer patients and 250 controls were included. Research information was obtained from their medical records. Blood samples were collected on admission. Serum concentration of programmed cell death ligand 1 was measured using Enzyme-Linked Immunosorbent Assay. The patients underwent cisplatin-etoposide chemotherapy with a maximum of six cycles. Subsequently, they were followed-up for 12 months, and therapeutic response and cancer death were recorded.ResultsSerum concentration of programmed cell death ligand 1 was higher in the patients than in the controls on admission (P < 0.001). After chemotherapy, 112 patients had no response to this therapy. In the 12-month follow up period, 118 patients died due to this cancer. Multivariate Cox regression model revealed that the higher serum concentration of programmed cell death ligand 1 on admission was associated with the higher risk of no response to chemotherapy or cancer caused death (HR: 1.40, 95% CI: 1.05 ~ 1.87; HR: 1.43, 95% CI: 1.08 ~ 1.87).ConclusionElevated serum concentration of soluble programmed cell death ligand 1 might be an independent risk factor for non-response to chemotherapy and cancer caused death in small cell lung cancer patients.

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

“…One study was excluded for cases less than 20 ( 38 ). Two studies focusing on small-cell lung cancer ( 39 ) and lung carcinomas ( 40 ) were excluded. Finally, eight studies ( 20 , 41 – 47 ) were included in this study.…”

Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis

“…The majority of patients are diagnosed with metastatic diseases at the initial visit, which highlights the importance of effective systemic therapies (3). The traditional therapy is chemotherapy, and certain gene expression patterns (4,5) and liquid biomarkers (6,7) serve as predictors of chemotherapy outcomes. Targeted therapy with small molecule tyrosine…”

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

“…In the subgroup analysis of patients receiving immunotherapy, patients with high sPD-L1 levels were correlated with a worse OS. An NSCLC study showed that the death risk in patients with high levels of sPD-L1 was 2.68 (95%CI 1.36–5.28) times the risk in patients with low sPD-L1 levels ( 14 ). Given that sPD-L1 can be derived from tumor tissue cells, the level of sPD-L1 can reflect tumor regression to a certain extent.…”